Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

This study has been completed.
Information provided by:
Takeda Identifier:
First received: September 12, 2005
Last updated: July 20, 2010
Last verified: July 2010
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.

Condition Intervention Phase
Drug: Lansoprazole
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label Multicenter Study to Evaluate the Pharmacodynamics of Intravenous Lansoprazole to That of Oral Lansoprazole in Subjects With Erosive Esophagitis

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Maximal Acid Output obtained 22 hours after the last dose of IV lansoprazole compared to the Maximal Acid Output obtained 22 hours after the last dose of oral lansoprazole following pentagastrin stimulation in both instances. [ Time Frame: Day 7 vs Day 15 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Basal Acid Output obtained 21 hours after the last dose of IV lansoprazole compared with that obtained 21 hours after the last dose of oral lansoprazole. [ Time Frame: Day 7 vs Day 15 ] [ Designated as safety issue: No ]
  • Maximum Acid Output and Basal Acid Output measurements obtained 21 hours and 22 hours, respectively, after the first dose of IV lansoprazole versus those obtained after the last dose of oral lansoprazole. [ Time Frame: Day 7 vs Day 8 ] [ Designated as safety issue: No ]
  • Maximum Acid Output and Basal Acid Output results obtained after the first versus last dose of IV lansoprazole. [ Time Frame: Day 8 vs Day 15 ] [ Designated as safety issue: No ]

Enrollment: 68
Study Start Date: June 2003
Study Completion Date: October 2003
Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lansoprazole IV 30 mg QD Drug: Lansoprazole
Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
Active Comparator: Lansoprazole Capsule 30 mg QD Drug: Lansoprazole
Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
Other Name: AG-1749

Detailed Description:
Phase 2, open label, multi-center, 2-period study to compare the pharmacodynamics of IV lansoprazole 30 mg to oral lansoprazole 30 mg in subjects with erosive esophagitis (grade >or= 2)diagnosed by endoscopy.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects were required to have Grade 2, 3 or 4 esophageal findings according to the TAP Grading Scale during the pretreatment endoscopy.
  • Subjects must discontinue histamine H2-receptor antagonists, proton pump ® inhibitors, prokinetic agents, antacids and Carafate before the first dose of drug and during the study.

Exclusion Criteria:

  • Gastric or duodenal ulcer (a lesion with appreciable depth ≥3 mm) or a hiatal hernia >5 cm.
  • Subjects could not have a diagnosis of Barrett's esophagus (with or without dysplastic changes).
  • Co-existing systemic disease affecting the esophagus, (ie, scleroderma, viral or fungal infection), radiation therapy to the region of the esophagus, or caustic or physiochemical trauma to the esophagus.
  • Current esophageal stricture requiring dilatation. The endoscope had to pass freely into the stomach during endoscopy. Any strictures could not have been dilated within 12 weeks before beginning the Pretreatment Period.
  • Positive H pylori by rapid urease test (CLO® test Kimberly-Clark Corporation).
  • Uncontrolled, clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, gastrointestinal, neurological or endocrine disease or other abnormality (other than the erosive esophagitis disease being studied).
  • Diagnosis of Zollinger-Ellison syndrome, esophageal varices, symptomatic pancreaticobiliary tract disease, cholecystitis, rheumatoid arthritis, lupus, or malignancy (except basal cell carcinoma).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00175045

Sponsors and Collaborators
Study Director: Medical Director Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Sr. VP Clinical Sciences, Takeda Global Research & Development Center, Inc. Identifier: NCT00175045     History of Changes
Other Study ID Numbers: C02-039  U1111-1114-2148 
Study First Received: September 12, 2005
Last Updated: July 20, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
gastric acid secretion

Additional relevant MeSH terms:
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Anti-Ulcer Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Proton Pump Inhibitors
Therapeutic Uses processed this record on February 10, 2016